SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing heightened market volatility and active investor debate following reports that Berkshire Hathaway has fully exited its stake in the company. While some traders view this as a potential risk-off signal that could trigger a near-term reprice, others are dismissing the move as noise, pointing to the company's resilient fundamentals, strong earnings outlook, and growing integration of AI into its operations as reasons to maintain a long-term bullish stance.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is facing intense scrutiny and volatility as investors grow frustrated with the stock's underperformance relative to Ethereum, fueled by debates over management's accumulation strategy and broader crypto market stagnation. While some community members view recent price dips as a long-term accumulation opportunity ahead of potential legislative clarity, others are actively calling out the CEO for failed price projections and aggressive dilution.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for an oral plenary presentation at the AUA Annual Meeting featuring highly anticipated extended follow-up data for its prostate cancer therapy, CAN-2409. Community discussion is intensely focused on the potential for this data to establish a new standard of care, with significant speculation surrounding the drug's long-term durability and its appeal as a premium buyout candidate for major pharmaceutical firms.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant trading volume and upward price momentum as investors rotate into semiconductor testing names, drawing comparisons to peers in the AI and EV chip supply chain. The community is actively debating the company's valuation gap relative to its sector, focusing on recent revenue growth, successful capacity expansion in Southeast Asia, and speculative interest in potential hyperscaler partnerships.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's Inc. (M) is trending after reporting a quarterly earnings beat and raising its full-year guidance, driven by successful store revamps and strength in its luxury Bloomingdale's and Bluemercury divisions. While investors are actively discussing the potential for a share price recovery and buyout rumors, community sentiment remains mixed as some traders debate whether this momentum is a sustainable turnaround or just a temporary relief rally.

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Generate Biomedicines Inc

Generate Biomedicines is generating significant market buzz amid conflicting community reports regarding a potential stake by Nvidia, while traders debate the impact of recent insider activity and the company's generative AI-driven drug discovery platform.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is trending as the community speculates on a potential price rally, driven by discussions around token burn proposals, deflationary tokenomics, and an updated product roadmap. Traders are closely monitoring the asset for a breakout, citing its low market cap and potential for high volatility as key reasons for their interest.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending due to significant community optimism surrounding the progress of the CLARITY Act and the launch of new XRP spot ETFs, which are fueling institutional demand. Despite broader market volatility, discussions are focused on the asset's long-term utility in cross-border payments and potential legal clarity as a digital commodity.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending as community members rally around its meme coin ecosystem and positive price movement, while traders debate the potential impact of legislative developments like the Clarity Act. The discussion is heavily driven by retail enthusiasm for established projects and speculative interest in new assets built on the Solana blockchain.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen is trending as market participants debate its turnaround potential, with investors closely watching for a breakout driven by menu innovation and operational efficiencies. The community remains deeply divided, with bulls pointing to insider buying and the brand's cult status, while skeptics emphasize concerns over profitability, widening losses, and stiff competition within the fast-casual sector.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karyopharm Therapeutics Q1 Earnings Call Highlights

Karyopharm Therapeutics Q1 Earnings Call Highlights...

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3...

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm to Participate at Upcoming Investor Conferences Karyopharm to Participate at Upcoming Investor Conferences PR Newswire NEWTON, Mass., May 12, 2026 NEWTON, Mass., May 12, 2026 /PRNewswire...

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 PR Newswire NEWTON, Mass., May 7, 2026...

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $13.00 at HC Wainwright

HC Wainwright lifted their target price on Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday...

Karyopharm Therapeutics (KPTI) Projected to Post Quarterly Earnings on Monday

Karyopharm Therapeutics (NASDAQ:KPTI) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat.com...

Piper Sandler Reiterates Overweight Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

Piper Sandler reaffirmed an "overweight" rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday...

$KPTI Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$1.02 up 63.18% YoY
• Reported revenue of $35.07M up 16.83% YoY
• Karyopharm reaffirms full-year 2026 total revenue guidance of $130 million to $150 million, including U.S. XPOVIO net product revenue of $115 million to $130 million for Karyopharm.

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.02 up 63.18% YoY
• Reported revenue of $35.07M up 16.83% YoY
• Karyopharm reaffirms full-year 2026 total revenue guidance of $130 million to $150 million, including U.S. XPOVIO net product revenue of $115 million to $130 million for Karyopharm.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

KPTI
Karyopharm Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Earnings Recap

Latest KPTI News

KPTIKaryopharm Therapeutics Inc